Ladybon

Tibolone, the active ingredient in Ladybon, is a synthetic steroid presented as an oral formulation for systemic use. It is prescribed to alleviate menopausal symptoms and to help maintain bone density in post‑menopausal women. GNH USA supplies Ladybon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ladybon (tibolone) is used within hormone replacement therapy to address conditions linked to menopause and bone health.

Menopausal symptoms: reduces hot flashes, night sweats and mood swings in post‑menopausal women. Osteoporosis prevention: improves bone mineral density and reduces fracture risk in post‑menopausal patients. Hormone replacement therapy: provides combined estrogenic, progestogenic and androgenic activity for overall symptom control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Breast tenderness: transient discomfort. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Venous thromboembolism: risk of deep vein thrombosis or pulmonary embolism. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Hormone‑dependent cancers: potential increase in breast or endometrial cancer risk.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Cardiovascular assessment: review history of thrombosis or stroke. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Breast evaluation: conduct regular clinical breast exams and imaging as indicated. - Bone health review: assess baseline bone mineral density. - Pregnancy contraindication: avoid use in pregnant or breastfeeding women. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Tibolone may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Combined oral contraceptives: may increase thrombotic risk. - Anticoagulants: potential for altered clotting parameters.

Moderate Interactions (Monitor Closely): - SSRIs: may diminish vasomotor symptom relief. - Antihypertensives: possible additive blood pressure effects. - Thyroid hormone replacement: may require dose adjustment.